Video will be live on Monday, June 23 at 1:00 PM Central Time.
▪️ Join my channel to get access to perks or simply subscribe and turn on your notifications!
▪️ Download my FREE GLP-1/GIP Medication Information Sheet and 7-Day Best Weight Journal here.
▪️ Join my Empowerment Hub and discover sustainable, evidence-based solutions to transform your health and embrace self-care without guilt.
👉 Enjoy lifetime free access to Daily Momentum and Nourish & Thrive, your go-to spaces for daily support, encouragement, and practical tips. Or, become a Core Member for just $15/month or $145/year to unlock expert coaching, exclusive resources, and a proven system that includes live Q&As and monthly toolkits, to help you create real, lasting change.
🔗 https://drdans-empowermenthub.mn.co
–
GLP-1 Plot Twist: The Most Underrated Drug Isn’t from the US
What if one of the most promising new weight loss medications isn’t from the U.S.—but China?
Mazdutide, a dual GLP-1/glucagon receptor agonist developed in China, is generating global buzz. We walk through the GLORY-1 trial data, what the weight loss results really show, and how this drug compares to heavyweights like Wegovy and Zepbound.
Mazdutide’s 6mg dose led to 14% weight loss at 48 weeks—but the study’s lower average BMI and a mysterious plateau around Week 32 raise important questions. I unpack potential reasons for the flatline, discuss the role of visceral fat, and highlight why placebo performance matters more than you think. We also touch on safety, limitations, and why early 9mg data could make Mazdutide a true contender.
With backing from Innovent and Eli Lilly, and a rapidly growing obesity market in China, this isn’t just a treatment story—it’s a strategic one. Could Mazdutide become a serious global rival? Let’s take a closer look at what the data—and the bigger picture—suggest.
Reference: Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, Zhao Y, Qiu W, Huang C, Chen L, Zhong S, Han J, Zhang Y, Lian Q, Yang P, Lv L, Gu J, Liu Z, Deng H, Wang Y, Li L, Pei L, Qian L; GLORY-1 Investigators. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025 May 25. doi: 10.1056/NEJMoa2411528. Epub ahead of print. PMID: 40421736.
Thanks for watching and always remember: small tweaks lead to massive peaks!
–
Don’t forget to hit the subscribe button for more insightful content, and consider joining our YouTube Members Membership for exclusive content and early access to weekly videos.
–
📺 Watch These Next:
▪️ Watch This Before Taking Mounjaro
▪️ From Ozempic to Mounjaro
▪️ Muscle Loss with Ozempic, Wegovy & Mounjaro
▪️ Managing Nausea from Ozempic, Wegovy and Trulicity!
▪️ Ozempic: Stomach Paralysis Update
▪️ How to Switch from Ozempic (or Wegovy) to Mounjaro
▪️ Ozempic Paralyzed My Stomach
▪️ How to Inject Mounjaro: step-by-step tutorial
–
🎯 Free Resources:
▪️ GLP-1/GIP Medication Info Sheet + 7-Day Food Journal
▪️ Total Daily Energy Expenditure (TDEE) Calculator – Find your optimal calorie intake
–
🛒 Recommended Products for Your Weight-Loss Journey:
▪️ Managing Constipation
▪️ Managing Heartburn
▪️ Protein Bars & Supplements
▪️ Activity Trackers & Scales
–
Live in Alberta? Come see me at my Pharmacist-led Obesity Clinic at Apothecare Pharmacy – http://apothecarerx.ca
–
Dr. Dan
Follow me on social media for regular updates – @TheOfficialDrDan
Subscribe to my newsletter for a heads-up on all new content.
Sharing is caring! Here’s the social, email, and even text link –
https://healthevolved.co/mazdutide
If you need some coaching support on your weight management journey, you can book a consultation with me to see if you’d be a good fit for our program.
Questions or comments? Please send them my way on our Contact Us page!
